Cargando…

Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model

Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakshinamoorthy, Gajalakshmi, von Gegerfelt, Agneta, Andersen, Hanne, Lewis, Mark, Kalyanasundaram, Ramaswamy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234504/
https://www.ncbi.nlm.nih.gov/pubmed/25401783
http://dx.doi.org/10.1371/journal.pone.0112982
_version_ 1782344874512613376
author Dakshinamoorthy, Gajalakshmi
von Gegerfelt, Agneta
Andersen, Hanne
Lewis, Mark
Kalyanasundaram, Ramaswamy
author_facet Dakshinamoorthy, Gajalakshmi
von Gegerfelt, Agneta
Andersen, Hanne
Lewis, Mark
Kalyanasundaram, Ramaswamy
author_sort Dakshinamoorthy, Gajalakshmi
collection PubMed
description Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection and eradicate the disease. Previously we reported that a multivalent fusion protein vaccine (rBmHAT) composed of small heat shock proteins 12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and large extracellular domain of tetraspanin (TSP LEL) could confer >95% protection against the challenge infection with Brugia malayi infective larvae (L3) in mouse and gerbil models. In this study we evaluated the immunogenicity and efficacy of rBmHAT fusion protein vaccine in a rhesus macaque model. Our results show that rBmHAT is highly immunogenic in rhesus macaques. All the vaccinated monkeys developed significant titers of antigen-specific IgG antibodies against each of the component antigens (16,000 for rBmHSP12.6), (24,000 for rBmALT-2) and (16,000 for rBmTSP-LEL). An in vitro antibody dependent cellular cytotoxicity (ADCC) assay performed using the sera samples from vaccinated monkeys showed that the anti-rBmHAT antibodies are functional with 35% killing of B. malayi L3s. Vaccinated monkeys also had antigen responding cells in the peripheral blood. Vaccine-induced protection was determined after challenging the monkeys with 500 B. malayi L3. Following challenge infection, 3 out of 5 vaccinated macaques failed to develop the infection. These three protected macaques had high titers of IgG1 antibodies and their PBMC secreted significantly high levels of IFN-γ in response to the vaccine antigens. The two vaccinated macaques that picked the infection had slightly low titers of antibodies and their PBMC secreted high levels of IL-10. Based on these findings we conclude that the rBmHAT vaccine is highly immunogenic and safe and can confer significant protection against challenge infections in rhesus macaques.
format Online
Article
Text
id pubmed-4234504
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42345042014-11-21 Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model Dakshinamoorthy, Gajalakshmi von Gegerfelt, Agneta Andersen, Hanne Lewis, Mark Kalyanasundaram, Ramaswamy PLoS One Research Article Lymphatic filariasis affects 120 million people worldwide and another 1.2 billion people are at risk of acquiring the infection. Chemotherapy with mass drug administration is substantially reducing the incidence of the infection. Nevertheless, an effective vaccine is needed to prevent the infection and eradicate the disease. Previously we reported that a multivalent fusion protein vaccine (rBmHAT) composed of small heat shock proteins 12.6 (HSP12.6), abundant larval transcript-2 (ALT-2) and large extracellular domain of tetraspanin (TSP LEL) could confer >95% protection against the challenge infection with Brugia malayi infective larvae (L3) in mouse and gerbil models. In this study we evaluated the immunogenicity and efficacy of rBmHAT fusion protein vaccine in a rhesus macaque model. Our results show that rBmHAT is highly immunogenic in rhesus macaques. All the vaccinated monkeys developed significant titers of antigen-specific IgG antibodies against each of the component antigens (16,000 for rBmHSP12.6), (24,000 for rBmALT-2) and (16,000 for rBmTSP-LEL). An in vitro antibody dependent cellular cytotoxicity (ADCC) assay performed using the sera samples from vaccinated monkeys showed that the anti-rBmHAT antibodies are functional with 35% killing of B. malayi L3s. Vaccinated monkeys also had antigen responding cells in the peripheral blood. Vaccine-induced protection was determined after challenging the monkeys with 500 B. malayi L3. Following challenge infection, 3 out of 5 vaccinated macaques failed to develop the infection. These three protected macaques had high titers of IgG1 antibodies and their PBMC secreted significantly high levels of IFN-γ in response to the vaccine antigens. The two vaccinated macaques that picked the infection had slightly low titers of antibodies and their PBMC secreted high levels of IL-10. Based on these findings we conclude that the rBmHAT vaccine is highly immunogenic and safe and can confer significant protection against challenge infections in rhesus macaques. Public Library of Science 2014-11-17 /pmc/articles/PMC4234504/ /pubmed/25401783 http://dx.doi.org/10.1371/journal.pone.0112982 Text en © 2014 Dakshinamoorthy et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Dakshinamoorthy, Gajalakshmi
von Gegerfelt, Agneta
Andersen, Hanne
Lewis, Mark
Kalyanasundaram, Ramaswamy
Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title_full Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title_fullStr Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title_full_unstemmed Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title_short Evaluation of a Multivalent Vaccine against Lymphatic Filariasis in Rhesus macaque Model
title_sort evaluation of a multivalent vaccine against lymphatic filariasis in rhesus macaque model
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4234504/
https://www.ncbi.nlm.nih.gov/pubmed/25401783
http://dx.doi.org/10.1371/journal.pone.0112982
work_keys_str_mv AT dakshinamoorthygajalakshmi evaluationofamultivalentvaccineagainstlymphaticfilariasisinrhesusmacaquemodel
AT vongegerfeltagneta evaluationofamultivalentvaccineagainstlymphaticfilariasisinrhesusmacaquemodel
AT andersenhanne evaluationofamultivalentvaccineagainstlymphaticfilariasisinrhesusmacaquemodel
AT lewismark evaluationofamultivalentvaccineagainstlymphaticfilariasisinrhesusmacaquemodel
AT kalyanasundaramramaswamy evaluationofamultivalentvaccineagainstlymphaticfilariasisinrhesusmacaquemodel